U.S. Biotech Stock News

Shift4 Payments (NYSE:FOUR) has partnered with xAI to integrate AI assistants into its customer service operations. The company is also pushing ahead with international expansion initiatives. Shift4 has completed its acquisition of Bambora North America, adding a large merchant base to its network. The Bambora deal is expected to broaden Shift4's integrated payments platform and create new cross-sell opportunities. Shift4 Payments comes into this news cycle after a difficult share price...

In February 2026, Sysco Corporation reported fiscal second-quarter revenue and earnings growth that exceeded analyst expectations and raised its adjusted earnings per share guidance for fiscal 2026 toward the upper end of its prior range, supported by strong international segment performance and improved operating leverage. This guidance upgrade, alongside Sysco’s expanding role in initiatives such as locally sourced products and nationwide distribution partnerships, highlights management’s...

Coinbase Global (NasdaqGS:COIN) has launched commission free, 24 hour trading for U.S. stocks and ETFs. The new service brings traditional securities onto Coinbase’s platform alongside crypto assets. The move marks an expansion of Coinbase’s product set beyond its core crypto trading business. Coinbase Global, trading at $182.36 as of the last close, is extending its reach beyond crypto by adding commission free U.S. stock and ETF trading that runs around the clock. The company’s shares are...

Best Buy FY 2026 results: revenue steady, EPS under pressure as margins stay thin Best Buy (BBY) has reported third quarter FY 2026 results with revenue of US$9.7b and basic EPS of US$0.66, setting the tone for a year where earnings quality is very much in focus. Over the past three quarters of FY 2026, revenue has ranged from US$8.8b to US$9.7b while basic EPS moved from US$0.95 in Q1 to US$0.88 in Q2 and US$0.66 in Q3, alongside same store sales trends that went from a 0.7% decline in Q1 to...

TETRA Technologies, Inc. reported its fourth-quarter and full-year 2025 results, with quarterly sales rising to US$146.68 million but swinging from prior-year net income of US$102.72 million to a net loss of US$16.5 million, while full-year revenue increased to US$630.93 million and net income fell to US$3.01 million. Despite the sharp drop in reported earnings, management highlighted a record year in 2025 driven by offshore completion fluids, stronger adjusted profitability measures, and...

Why Murphy Oil’s Ivory Coast update matters for investors Murphy Oil (MUR) told investors its Caracal-1X exploration well offshore Ivory Coast will be plugged and abandoned as a dry hole, and the company and PETROCI will continue with the Bubale-1X prospect. See our latest analysis for Murphy Oil. Murphy Oil’s recent Ivory Coast update sits against a backdrop of strong momentum, with a 7.33% year to date share price return at a US$34.87 share price and a 50.05% one year total shareholder...

Oracle (ORCL) is back in the spotlight as multiple securities fraud class action lawsuits, heavy AI infrastructure spending, and fresh analyst upgrades collide to raise new questions about risk, funding needs, and long-term opportunity. See our latest analysis for Oracle. Those class action filings and funding headlines have come during a period of weaker momentum, with a 30 day share price return of 9.46% and a 90 day share price return of 28.27%. This contrasts with the 3 year total...

Universal Insurance Holdings (UVE) released fourth quarter and full year 2025 results, reporting higher revenue and net income than a year earlier, along with an update on its recently completed share repurchase activity. See our latest analysis for Universal Insurance Holdings. The latest results and completed buyback have come alongside strong share price momentum, with a 30 day share price return of 18.19% and a 1 year total shareholder return of 71.31%. This suggests investors have been...

In late February 2026, Eli Lilly reported a series of product updates, including positive EMA guidance for Olumiant in adolescents with severe alopecia areata, strong Phase 3 data for oral GLP-1 candidate orforglipron versus oral semaglutide, label expansion for Zepbound’s monthly KwikPen, and durable multi-year results for Omvoh in inflammatory bowel disease. These developments highlight how Lilly is broadening its cardiometabolic and immunology franchises beyond injectable GLP-1s,...

Recently, First BanCorp reported that widespread labor shortages across Puerto Rico, the U.S., the Virgin Islands, and other markets are disrupting many commercial clients’ operations, tightening supply chains, pressuring cash flows, and increasing the risk that some borrowers may struggle to meet loan obligations. The same labor constraints are raising First BanCorp’s own wage costs and creating staffing gaps, which could pressure service quality and introduce additional operational and...

Bitmine Immersion Technologies acquired 50,928 ETH, taking its total Ethereum holdings to more than 4.4 million. The move reinforces Bitmine's role as a large Ethereum treasury and expands its exposure to ETH staking. The company, which trades as NYSEAM:BMNR, last closed at $19.57. Bitmine Immersion Technologies (NYSEAM:BMNR) is leaning further into its Ethereum-focused model with this large purchase of ETH. The company already positions itself as an Ethereum treasury play, and this move...

If you are wondering whether St. Joe's current share price still offers value, it helps to step back and look at what the numbers are really saying about the business. The stock last closed at US$72.79, with returns of 4.0% over 7 days, 10.0% over 30 days, 21.7% year to date, 56.8% over 1 year, 82.4% over 3 years and 56.4% over 5 years, which will naturally raise questions about how the current price lines up with underlying value. Investors have been watching St. Joe as it continues to...

Affirm Holdings (AFRM) is back in focus after announcing an expanded partnership with Stripe that will add its pay over time financing to Shared Payment Tokens used in AI driven shopping and checkout experiences. See our latest analysis for Affirm Holdings. Despite the Stripe and AI commerce news putting Affirm back in the headlines, the share price at US$47.83 reflects a 30 day share price return decline of 20.68% and a 90 day share price return decline of 31.32%, while the 3 year total...

In late February 2026, CNX Resources completed a private placement of US$500,000,000 in 5.875% senior notes due 2034, guaranteed by its restricted subsidiaries and sold to qualified institutional and non-U.S. investors under Rule 144A and Regulation S. CNX is using the proceeds to retire its 6.000% senior notes due 2029 through a tender offer and redemption, reshaping its debt profile and interest obligations. We’ll now examine how refinancing 6.000% 2029 notes with 5.875% 2034 notes could...

Leadership additions reshape Evercore’s sector and regional focus Evercore (EVR) has been in focus after appointing Ben Carpenter to strengthen its healthcare and biopharma investment banking practice and Ben Hart to lead Asia Private Capital Advisory, signaling a push in sector and regional coverage. See our latest analysis for Evercore. Despite the recent appointments and other corporate updates, Evercore’s share price has eased back, with a 30 day share price return of a 12.88% decline,...

Wondering if BOK Financial is offering real value at its current share price, or if most of the upside is already priced in? This article walks through the numbers so you can judge how the stock stacks up. The share price last closed at US$128.46, with returns of a 0.6% decline over 7 days, a 1.1% decline over 30 days, 8.2% year to date, 25.3% over 1 year and 55.0% over 5 years, which gives plenty of history to assess how the market has priced the business. Recent coverage around BOK...

If you are wondering whether ADT is attractively priced today or if the security specialist is a potential value trap in your portfolio, this article is for you. ADT shares last closed at US$6.85, with returns of a 13.1% decline over 7 days, a 14.4% decline over 30 days, a 14.5% decline year to date and a 7.3% decline over 1 year, while the 5 year return sits at 0.9%. These moves have kept ADT on many investors' watchlists, especially among those focused on how sentiment about home and...

In late February 2026, The Schall Law Firm began investigating Rambus Inc. for potential securities law violations after the company disclosed a supply chain disruption affecting its first-quarter 2026 operations. This combination of legal scrutiny and operational strain raises fresh questions about Rambus’s disclosure practices and operational resilience at a time when it is repositioning itself as a core supplier to AI memory infrastructure. We’ll now examine how the investigation into...

If you have ever looked at Lockheed Martin and wondered whether the current share price really matches its underlying value, you are not alone. The stock most recently closed at US$667.82, with returns of 0.5% over 7 days, 5.3% over 30 days, 34.4% year to date, 52.9% over 1 year, 51.2% over 3 years and 126.5% over 5 years. Recent headlines have continued to focus on Lockheed Martin as a key global defense contractor, with investors paying close attention to contract activity, geopolitical...

Constellium (CSTM) is back in the spotlight after reporting fourth quarter and full year 2025 results, with sales of US$2,201 million in the quarter and a shift from a net loss to net income. See our latest analysis for Constellium. The strong quarterly and full year results, together with the recently completed share buyback and sustainability update, come after a powerful run in the shares, with a 30.65% year to date share price return and a very large 153.98% total shareholder return over...

Yatsen Holding (NYSE:YSG) has capped FY 2025 with fourth quarter revenue of C¥1.4b and basic EPS of C¥0.09, a clear contrast to the loss profile seen earlier in the year. The company has seen quarterly revenue move from C¥833.5m in Q1 2025 to C¥1.4b in Q4, while basic EPS has shifted from a loss of C¥0.06 in Q1 and C¥0.19 in Q2 to a profit in Q4, against a trailing twelve month EPS of a C¥1.35 loss and net income loss of C¥80.9m on C¥4.3b of revenue. That mix of stronger recent EPS and still...

In late February 2026, Regeneron Pharmaceuticals and Sanofi reported U.S. FDA approval of Dupixent for allergic fungal rhinosinusitis in patients aged 6 and older with prior sino-nasal surgery, while securing a positive EU opinion for pediatric chronic spontaneous urticaria and Priority Review for garetosmab in fibrodysplasia ossificans progressiva. These updates underscore how Regeneron is broadening Dupixent’s reach across difficult-to-treat type 2 inflammatory diseases while advancing an...

If you are trying to work out whether Aon’s current share price gives you value or not, this article will walk through what the numbers actually say rather than just the headline moves. Aon recently closed at US$339.07, with returns of 6.2% over the past week, a 3.0% decline over the last month, a 1.5% decline year to date, and longer term returns of 15.2% over 3 years and 52.4% over 5 years, alongside a 15.5% decline over the past year. Recent news around Aon has largely focused on its role...

iHeartMedia (IHRT) closed out Q4 FY 2025 with revenue of US$1.1 billion and a basic EPS loss of US$0.27, as net income excluding extra items came in at a loss of US$41.9 million. Trailing 12 month figures showed revenue of US$3.9 billion and a basic EPS loss of US$3.05 tied to a net loss of US$472.9 million. Over recent quarters, the company has seen revenue range from US$807.1 million in Q1 2025 to US$1.1 billion in Q4 2025, alongside quarterly EPS losses between US$0.27 and US$1.84. This...